rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BBH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Simplify Health Care ETF vs. VanEck Biotech ETF: One Critical Difference Could Shape Future Returns | The Motley Fool

      These two healthcare ETFs take fundamentally different approaches to investing, with meaningful differences in diversification, management strategy, and long-term return potential.

      Nov 12The Motley FoolBBHDESKPINK
      Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? | The Motley Fool

      BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

      Oct 27The Motley FoolBBHIVZDESK
      VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? | The Motley Fool

      These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

      Oct 25The Motley FoolBBHIVZDESKRSPH
      Biotech ETF (BBH) Hits New 52-Week High
      Oct 21Yahoo FinanceBBH
      Better Biotechnology ETF: First Trust FBT vs. VanEck BBH | The Motley Fool

      VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

      Oct 10The Motley FoolBBHDESKFBT
      Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma | The Motley Fool

      BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

      Oct 10The Motley FoolBBHDESKXPH
      VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? | The Motley Fool

      PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

      Sep 15The Motley FoolBBHPPHDESK
      Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? | The Motley Fool

      VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.

      Aug 28The Motley FoolBBHIVZDESK
      BBH: Biotech’s Next Growth Cycle Is Just Getting Started (NASDAQ:BBH)
      Aug 24Seeking AlphaBBH
      Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? | The Motley Fool

      VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.

      Aug 22The Motley FoolBBHIBBQDESK

      This is the newest page. Registered accounts read further back.